Amgen’s promising gastric cancer drug makes good on Five Prime potential with FDA’s breakthrough nod

When Five Prime — now part of Amgen — rolled out mid-stage data for gastric cancer candidate bemarituzumab late last year, it looked like a big win with one major catch: The drug missed its OS primary endpoint. Even still, there was enough promise for Amgen to jump aboard, and...

Click to view original post